ME00930B - Progesterone for the prevention of preterm birth - Google Patents

Progesterone for the prevention of preterm birth

Info

Publication number
ME00930B
ME00930B MEP-2009-265A MEP26509A ME00930B ME 00930 B ME00930 B ME 00930B ME P26509 A MEP26509 A ME P26509A ME 00930 B ME00930 B ME 00930B
Authority
ME
Montenegro
Prior art keywords
progesterone
pregnant women
preterm birth
prevention
cervix
Prior art date
Application number
MEP-2009-265A
Other languages
French (fr)
Unknown language (me)
Inventor
George Creasy
Brien Jr John M O'
Emily A Defranco
Kenneth N Muse
Original Assignee
Columbia Laboratories Bermuda Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39301249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME00930(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Columbia Laboratories Bermuda Ltd filed Critical Columbia Laboratories Bermuda Ltd
Publication of ME00930B publication Critical patent/ME00930B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Postupak  za  lečenje   ili  prevencjju  spontanog  prevremenog   porođaja   kod  trudnica  i poboljšavanje neonatalnog morbiditeta i smrtnosti. Postupak obuhvata davanje trudnicama efikasne  količine  progesterna  dovoljne da produži  trudnoću  minimiziranjem skraćivanja  ili  otvaranja  njihovog  grlića. Tretman  i profilaksa progesteronom  trudnica koje  imaju  simpotme   kratkog   grlića  je  klinički  dokazano   da  povećava   neonatalno zdravlje.A procedure for treating or preventing spontaneous preterm birth in pregnant women and improving neonatal morbidity and mortality. The procedure involves giving pregnant women an effective amount of progesterone sufficient to prolong their pregnancy by minimizing the shortening or opening of their cervix. Treatment and prophylaxis with progesterone of pregnant women with symptoms of short cervix has been clinically proven to increase neonatal health.

MEP-2009-265A 2007-02-06 2008-02-05 Progesterone for the prevention of preterm birth ME00930B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88848007P 2007-02-06 2007-02-06
US97366707P 2007-09-19 2007-09-19
PCT/GB2008/000397 WO2008096122A2 (en) 2007-02-06 2008-02-05 Progesterone for the prevention of preterm birth

Publications (1)

Publication Number Publication Date
ME00930B true ME00930B (en) 2012-03-20

Family

ID=39301249

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2009-265A ME00930B (en) 2007-02-06 2008-02-05 Progesterone for the prevention of preterm birth

Country Status (24)

Country Link
US (2) US8828981B2 (en)
EP (1) EP2117554B1 (en)
JP (2) JP5580601B2 (en)
KR (1) KR101546101B1 (en)
AR (1) AR065179A1 (en)
AU (1) AU2008212724A1 (en)
BR (1) BRPI0807203A2 (en)
CA (1) CA2677354C (en)
CL (1) CL2008000375A1 (en)
CO (1) CO6220941A2 (en)
CR (1) CR10985A (en)
ES (1) ES2596803T3 (en)
GE (1) GEP20135727B (en)
HK (1) HK1136975A1 (en)
IL (1) IL200272A (en)
MA (1) MA31200B1 (en)
ME (1) ME00930B (en)
MX (1) MX2009008409A (en)
MY (1) MY184866A (en)
NZ (1) NZ579114A (en)
PE (1) PE20081738A1 (en)
RU (1) RU2524617C2 (en)
TW (1) TWI471135B (en)
WO (1) WO2008096122A2 (en)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2401036T3 (en) 2002-08-13 2013-04-16 N-Dia, Inc. Use of devices and methods to detect amniotic fluid in vaginal secretions
US8828981B2 (en) 2007-02-06 2014-09-09 George Creasy Progesterone for the treatment or prevention of spontaneous preterm birth
CA3016642A1 (en) 2008-02-04 2009-08-13 Ferring B.V. Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof
CA2738605A1 (en) 2008-09-24 2010-04-01 Luke Anthony O'neill Composition and method for treatment of preterm labor
GB0905964D0 (en) * 2009-04-06 2009-05-20 King S College London Marker
WO2011079047A1 (en) * 2009-12-23 2011-06-30 Drugtech Corporation Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions
EP2544707B1 (en) * 2010-03-09 2018-11-21 Dignity Health Methods for inhibiting preterm labor and uterine contractility disorders and preventing cervical ripening
US9375437B2 (en) 2010-06-18 2016-06-28 Lipocine Inc. Progesterone containing oral dosage forms and kits
US9271991B2 (en) 2010-10-27 2016-03-01 Dignity Health Trimegestone (TMG) for treatment of preterm birth
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
LT2782584T (en) 2011-11-23 2021-09-10 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
DE102012009057A1 (en) * 2012-05-09 2013-11-14 Dr. Arabin GmbH & Co. KG Rotational pessary made from a polymer comprises an active substance against premature births
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
EP2941644B1 (en) 2013-01-02 2019-09-11 Qiagen Sciences, LLC Methods for predicting time-to-delivery in pregnant women
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
WO2015198104A1 (en) * 2014-06-28 2015-12-30 Laboratorios Andromaco S.A. Cerclage pessary containing progesterone for prolonged, sustained and continuous release, used to prevent premature birth
KR20170040209A (en) 2014-07-29 2017-04-12 쎄러퓨틱스엠디, 인코퍼레이티드 Transdermal cream
KR101726488B1 (en) 2015-02-23 2017-04-13 이화여자대학교 산학협력단 Composition for the treatment of pregnancy-related diseases comprising the extracellular vesicles derived from Bacillus spp.
US9844558B1 (en) 2015-04-30 2017-12-19 Amag Pharmaceuticals, Inc. Methods of reducing risk of preterm birth
US20170035781A1 (en) * 2015-06-22 2017-02-09 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10231979B2 (en) * 2015-08-07 2019-03-19 Indiana University Research And Technology Corporation Modulation of inflammation using progesterone metabolites
WO2017040243A1 (en) * 2015-08-28 2017-03-09 Kypha, Inc. Methods for predicting flare and improving treatment of patients
US10556922B2 (en) 2015-09-29 2020-02-11 Amag Pharmaceuticals, Inc. Crystalline and amorphous forms of 17-alpha-hydroxyprogesterone caproate
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
EP3458070A4 (en) * 2016-05-16 2020-01-08 Amag Pharmaceuticals, Inc. Polymeric extended release compositions of hydroxyprogesterone caproate and methods of using same
US10656164B2 (en) 2016-12-22 2020-05-19 Qiagen Sciences, Llc Screening asymptomatic pregnant woman for preterm birth
US10935555B2 (en) 2016-12-22 2021-03-02 Qiagen Sciences, Llc Determining candidate for induction of labor
JP2018140172A (en) * 2017-02-28 2018-09-13 株式会社Ｎｔｔドコモ Data collection device and data collection method
US11207509B2 (en) 2017-06-15 2021-12-28 Wiesman Holdings, LLC Method and device for delivery of a solution into a body orifice
RU2657772C1 (en) * 2017-07-06 2018-06-15 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский институт акушерства и гинекологии" Министерства здравоохранения Московской области Method of preventing gestational complications in pregnant women with epilepsy
US20190038637A1 (en) * 2017-08-05 2019-02-07 Eric Marchewitz Use of Hydroxyprogesterone Derivatives for Enhanced Health and Physical Performance II
MX2020004421A (en) * 2017-10-30 2020-09-25 Carmentix Pte Ltd Biomarkers of preterm birth.
RU2692932C2 (en) * 2017-11-07 2019-06-28 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) BIOCATALYST FOR PRODUCING 11α-ACETOXYPROGESTERONE
USD918388S1 (en) 2018-06-15 2021-05-04 Wiesman Holdings, LLC Solution diffusing head
JP7301326B2 (en) * 2018-10-16 2023-07-03 公立大学法人横浜市立大学 Neonatal to childhood-onset cerebrovascular disease or method for detecting carriers thereof
KR102157438B1 (en) * 2019-04-16 2020-09-21 고려대학교 산학협력단 Method and Kit for diagnosing preterm birth
CN114728013A (en) * 2019-09-23 2022-07-08 斯坦福大学托管董事会 Methods of treating prolonged pregnancy and complications of menstruation or pregnancy
CN113164383B (en) 2019-10-12 2022-08-12 国家卫生健康委科学技术研究所 Vagina slow-release drug delivery system for corpus luteum support and preparation method and application thereof
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
KR102482468B1 (en) * 2020-08-11 2022-12-28 연세대학교 산학협력단 Methods for providing information about preterm birth and device using the same
US20220072008A1 (en) * 2020-09-08 2022-03-10 Cedars-Sinai Medical Center Method of using progesterone receptor agonists for the treatment of covid-19
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) * 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
DE4229820C2 (en) 1992-09-07 1998-12-03 Jenapharm Gmbh Progestogen-based pharmaceutical preparation
US5830848A (en) 1992-10-09 1998-11-03 The Regents Of The University Of California Method and agents for inducement of endogenous nitric oxide synthase for control and management of labor during pregnancy
US5948762A (en) 1993-07-16 1999-09-07 Schering Aktiengesellschaft Treatment of uterine contractility disorders with a nitric oxide synthase substrate and/or donor or a nitric oxide inhibitor
US5895783A (en) 1993-07-16 1999-04-20 Schering Aktiengesellschaft Treatment of preeclampsia and preterm labor with combination of progestational agent and a nitric oxide synthase substrate and/or donor
US5543150A (en) 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof
CZ292395B6 (en) 1995-03-14 2003-09-17 Schering Aktiengesellschaft Medicament for regulating cervical dilatation and extensibility
US5910482A (en) 1996-03-19 1999-06-08 Board Of Regents, The University Of Texas System Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor
US6040340A (en) 1996-05-07 2000-03-21 Schering Aktiengesellschaft Implantation rates after in vitro fertilization, treatment of infertility and early pregnancy loss with a nitric oxide donor alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors
US5744463A (en) 1996-06-03 1998-04-28 Bair; Glenn O. Treatment of side effects of progestins and progesterone analogues used for birth control
US5985861A (en) 1996-11-04 1999-11-16 Columbia Laboratories, Inc. Progesterone for treating or reducing ischemia
DE69819748T2 (en) 1997-09-12 2004-09-30 Columbia Laboratories (Bermuda) Ltd. MEDICINES FOR TREATING DYSMENORRHEA AND PREVIOUS BLIES
US6248358B1 (en) 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
US6306914B1 (en) 1997-10-21 2001-10-23 Columbia Laboratories, Inc. Progestin therapy for maintaining amenorrhea
US20020031513A1 (en) 1997-11-24 2002-03-14 Shamir Leibovitz Method and pharmaceutical composition for inhibiting premature rapture of fetal membranes, ripening of uterine cervix and preterm labor in mammals
US5941888A (en) 1998-02-18 1999-08-24 Target Therapeutics, Inc. Vaso-occlusive member assembly with multiple detaching points
IL127129A (en) 1998-11-18 2004-06-01 Ferring Bv Method for preparation of progesterone tablets for vaginal delivery and tablets so prepared
AU5683900A (en) 1999-06-21 2001-01-09 Columbia Laboratories (Bermuda) Limited Programming ovulation
US6375970B1 (en) 1999-07-07 2002-04-23 Andre Bieniarz Methods and materials for preterm birth prevention
AU2002313517B2 (en) 2001-08-31 2007-09-06 Bayer Schering Pharma Oy Drug delivery system
FR2832065B1 (en) 2001-11-13 2004-11-05 Besins Int Belgique PHARMACEUTICAL COMPOSITION BASED ON MICRONIZED PROGESTERONE, PREPARATION METHOD THEREOF AND USES THEREOF
FR2842108B1 (en) 2002-07-09 2008-05-02 Effik COMPOUNDS BASED ON HORMONE AND NITROGEN MONOXIDE AND THEIR USE IN OBSTETRICS AND GYNECOLOGY
ATE553378T1 (en) 2003-02-06 2012-04-15 Hologic Inc SCREENING AND TREATMENT PROCEDURES TO PREVENT PREMATURE BIRTH
BRPI0516247A (en) 2004-10-07 2008-08-26 Duramed Pharmaceuticals Inc hormonal treatment methods using increasing dose prolonged cycle regimens
CA2609192A1 (en) * 2005-05-26 2006-11-30 Duramed Pharmaceuticals, Inc. Oral dosage forms comprising progesterone and methods of making and using the same
US8828981B2 (en) 2007-02-06 2014-09-09 George Creasy Progesterone for the treatment or prevention of spontaneous preterm birth

Also Published As

Publication number Publication date
WO2008096122A2 (en) 2008-08-14
JP5580601B2 (en) 2014-08-27
CA2677354C (en) 2015-07-07
HK1136975A1 (en) 2010-07-16
US20080188829A1 (en) 2008-08-07
RU2009133315A (en) 2011-03-20
EP2117554A2 (en) 2009-11-18
CL2008000375A1 (en) 2008-05-30
NZ579114A (en) 2012-07-27
CR10985A (en) 2009-10-23
US20090264395A1 (en) 2009-10-22
PE20081738A1 (en) 2008-11-20
JP2010518058A (en) 2010-05-27
US7884093B2 (en) 2011-02-08
AU2008212724A1 (en) 2008-08-14
KR20090123875A (en) 2009-12-02
JP2014058529A (en) 2014-04-03
US8828981B2 (en) 2014-09-09
CA2677354A1 (en) 2008-08-14
RU2524617C2 (en) 2014-07-27
EP2117554B1 (en) 2016-07-13
BRPI0807203A2 (en) 2014-07-22
CO6220941A2 (en) 2010-11-19
TW200902030A (en) 2009-01-16
MA31200B1 (en) 2010-02-01
MX2009008409A (en) 2009-09-16
ES2596803T3 (en) 2017-01-12
IL200272A (en) 2014-02-27
MY184866A (en) 2021-04-28
GEP20135727B (en) 2013-01-25
WO2008096122A3 (en) 2009-02-26
IL200272A0 (en) 2010-04-29
TWI471135B (en) 2015-02-01
AR065179A1 (en) 2009-05-20
KR101546101B1 (en) 2015-08-20

Similar Documents

Publication Publication Date Title
ME00930B (en) Progesterone for the prevention of preterm birth
PH12017502350A1 (en) Nutritional compositions with 2fl and lnnt for use in inducing a gut microbiota close to the one of breast fed infants
PH12018502383A1 (en) Nutritional compositions with 2fl and lnnt for use in preventing and/or treating non-rotavirus diarrhea by acting on the gut microbiota dysbiosis
RU2013128594A (en) COMPOSITION FOR USE FOR THE PREVENTION AND / OR TREATMENT OF SKIN STATE AND DISEASES OF THE SKIN
BR112015024270A2 (en) disposable absorbent articles
BR112015018438A2 (en) c5 antibody and method for preventing and treating complement-related diseases
BR112015029056A2 (en) compound, and subcutaneously implantable pharmaceutical pill or tablet to treat a human suffering from endometriosis
BRPI0517799A (en) composition to facilitate human childbirth
ME01534B (en) 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl derivative, methods for the production thereof and use thereof for treating diseases
WO2010151755A3 (en) TREATMENT OF INFLAMMATORY DISEASES USING miR-124
BR112016026510A2 (en) DEVICE AND FORMULATION FOR TOPICAL TREATMENT OF PAIN AFFECTING THE VULVAR AREA OF THE FEMALE GENITAL ORGANIC
EA201490209A1 (en) TREATMENT OF EXCESSIVE MENSTRUAL BLEEDING, CAUSED BY FIBER UTERUS
PH12017500051A1 (en) Nutritional composition for use to treat or prevent pregnancy related conditions
BR112014030984A2 (en) compositions and methods for increasing the effectiveness of contraceptive microbicides
MY172530A (en) Method for treating gynecological diseases
CO2017007689A2 (en) Compositions and methods that use il-8 to increase milk production and improve reproductive health and inhibit hypercetonemia in mammals
Grandone et al. Assisted reproductive technologies and thrombosis
NZ626573A (en) Glutamine enriched nutritional composition for preterm infants
UA101474C2 (en) Use of a progesterone in the manufacture of a medicament
PH12015502160A1 (en) Use of specific carbohydrate systems during pregnancy for preventing fat accumulation in pregnant women
BR112015015370A2 (en) use of a salt and sugar combination in the manufacture of a medicament used to treat relaxed vagina syndrome or colpoxerosis disease in a mammal
WO2015057403A3 (en) Compositions and methods for treatment of inflammatory bowel disease
BRPI0800156A2 (en) Intimate Feminine Soap Soap Set and Soap Composition for Menstrual Use
Jang et al. 2 Cases of Qi Deficiency Type Menorrhagia with Gobonjibung-tang
Zuo To improve the diagnosis and treatment of caesarean scar pregnancy, and to reduce the damage to women reproduction--the understanding of «consensus on the diagnosis and treatment of caesarean scar pregnancy»